Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASUAL ECMO: Anticoagulation Strategies for ECMO Support
2024-518702-40-00Phase 4Authorised
- Sponsor
- Medical University of Vienna
- Start
- Dec 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in respiratory failure, Cardiovascular collapse, acute respiratory distress syndrome (ARDS) and 5 more comparing Unfractionated heparin arm, Argatroban arm and Low-molecular-weight heparin arm (3 arms). Primary endpoint: Incidence of thromboembolic events during ECMO therapy. Planned start Dec 2024; status: authorised.
02
Drugs
argatrobanheparinenoxaparin
03
Conditions
respiratory failureCardiovascular collapseacute respiratory distress syndrome (ARDS)viral infectioncardiac morbidity
Beyond the preview
Go deeper on 2024-518702-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518702-40-00.